GBX Intl Gr (OTC:GBXI) Stock, Quote.Headers.trade-ideas

GBX International Group Inc is a marketing and customer acquisition company. It provides local merchants, entrepreneurs, and charities with a unique marketing and advertising system that includes online tools, marketing materials and expertise that can help merchants and charities increase their customer bases, develop more repeat customers and expand their buying and giving communities. The company also offers local merchants discounted credit and debit card processing services provided by third party processors and earns income on ongoing transactions occurring at those locations.

GBX INTERNATIONAL GROUP by GBX International Group Inc.

GBX International Group Inc

Endava PLC&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dava#NYSE">DAVA</a>) came out with quarterly earnings of $0.28 per share, missing the Zacks Consensus Estimate of $0.29 per share. This compares to earnings of $0.71 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of -3.45%. A quarter ago, it was expected that this company would post earnings of $0.23 per share when it actually produced earnings of $0.28, delivering a surprise of 21.74%.
Over the last four quarters, the company has surpassed consensus EPS estimates two times.
Endava, which belongs to the Zacks Computers - IT Services industry, posted revenues of $245.3 million for the quarter ended June 2024, missing the Zacks Consensus Estimate by 1.35%. This compares to year-ago revenues of $237.56 million. The company has topped consensus revenue estimates two times over the last four quarters.
The sustainability of the stock&#39;s immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management&#39;s commentary on the earnings call.
Endava shares have lost about 62.9% since the beginning of the year versus the S&amp;P 500&#39;s gain of 17.8%.
<h2>What&#39;s Next for Endava?</h2>
While Endava has underperformed the market so far this year, the question that comes to investors&#39; minds is: what&#39;s next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company&#39;s earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Endava: mixed. While the magnitude and direction of estimate revisions could change following the company&#39;s just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $0.38 on $257.42 million in revenues for the coming quarter and $1.60 on $1.06 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Computers - IT Services is currently in the top 20% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Accenture (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/acn#NYSE">ACN</a>), another stock in the same industry, has yet to report results for the quarter ended August 2024. The results are expected to be released on September 26.
This consulting company is expected to post quarterly earnings of $2.77 per share in its upcoming report, which represents a year-over-year change of +2.2%. The consensus EPS estimate for the quarter has been revised 0% higher over the last 30 days to the current level.
Accenture&#39;s revenues are expected to be $16.33 billion, up 2.2% from the year-ago quarter.
<a href="https://www.zacks.com/stock/news/2338368/endava-plc-sponsored-adr-dava-misses-q4-earnings-and-revenue-estimates?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_4-2338368">To read this article on Zacks.com click here.</a>

Earnings

Earnings Misses

Large Cap

News

Small Cap

Markets

Analyst Ratings

Tech

Trading Ideas

DAVA

Endava PLC Misses Q4 Earnings and Revenue Estimates

Goldman Sachs analyst Ati Modak maintains MYR Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYRG#NASDAQ">MYRG</a>) with a Buy and lowers the price target from $182 to $124.

Price Target

MYRG

Goldman Sachs Maintains Buy on MYR Group, Lowers Price Target to $124

California Hospital Receives Robot Upgrade
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.knightscope.com%2F&amp;esheet=54124704&amp;newsitemid=20240919470351&amp;lan=en-US&amp;anchor=Knightscope%2C+Inc.&amp;index=1&amp;md5=ead5fafeedc285e9b59834e8c11d0b13">Knightscope, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KSCP#NASDAQ">KSCP</a>) ("Knightscope" or the "Company"), an innovator in robotics and artificial intelligence ("AI") technologies focused on public safety, today announces another security robot contract renewal in Texas and a robot upgrade for a California hospital.
 &nbsp;

KSCP

Knightscope Announces Another Security Robot Contract Renewal In Texas And A Robot Upgrade For A California Hospital

Goldman Sachs analyst Caitlin Burrows maintains Macerich (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAC#NYSE">MAC</a>) with a Sell and raises the price target from $13 to $14.6.

Goldman Sachs Maintains Sell on Macerich, Raises Price Target to $14.6

Goldman Sachs analyst Mike Burton maintains Cinemark Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNK#NYSE">CNK</a>) with a Sell and raises the price target from $16 to $20.

Goldman Sachs Maintains Sell on Cinemark Hldgs, Raises Price Target to $20

CNBC Halftime Report Final Trades: Target, The Home Depot, iShares Core S&P Small-Cap ETF

WIIM

ABNB

RYAAY

Shares of travel and hotel-related stocks are trading higher following Wednesday's Fed rate cut. Lower rates could stimulate growth and boost consumer spending.

Live On CNBC, Kevin Simpson Announces Bought More Freeport-McMoRan

TSLA

Tesla shares are trading higher amid overall market strength following Wednesday's Fed rate cut.

Wall Street is in full risk-on mode following the Federal Reserve&#8217;s landmark decision to slash interest rates by 50 basis points, signaling further cuts as inflation approaches <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40938732/wall-street-ramps-up-interest-rate-cut-bets-after-fed-meeting-the-hard-landing-crow">the central bank&#8217;s target.</a>
The S&amp;P 500 and Dow Jones both set fresh record highs during the morning session in New York, buoyed by strong performances from the Magnificent Seven tech giants.
By midday, these elite tech stocks added over $500 billion in market value, boosting their combined market capitalization to $15.9 trillion.
Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) led the rally, surging nearly 7% and hitting a two-month peak, while NVIDIA Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) climbed 5%, driving the semiconductor sector higher.
The iShares Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOXX#NASDAQ">SOXX</a>) jumped 4.6%, fully erasing its losses from September.
The Nasdaq 100 rose 2.9%, on pace for its strongest session in over a month and outperforming other major indices. Small caps joined the rally, with the Russell 2000 index surging 2%.
Commodities rallied across the board: Gold, silver, and copper increased by 1.2%, 3.8%, and 1.8%, respectively. Oil prices, tracked by the United States Oil Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USO#NYSE">USO</a>), spiked over 3%.
The bullish sentiment extended to cryptocurrencies, with Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) rising over 2%, poised to close at its highest level since late August.
<h1 class="wp-block-heading">Thursday&#8217;s Performance In Major U.S. Indices, ETFs</h1>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices </td>
<td>Price</td>
<td>1-day %chg</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>19,905.70</td>
<td>2.9%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,249.90</td>
<td>2.0%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,720.74</td>
<td>1.8%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>42,002.90</td>
<td>1.2%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 12:25 p.m. ET</figcaption></figure>
According to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent091924&amp;t=be2bearmibe3na1">Benzinga Pro</a> data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)&nbsp;was 1.8% higher to $571.52.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>)&nbsp;rose 1.2% to $421.23.</li>
<li>The tech-heavy Invesco QQQ Trust Series (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) rallied 2.8% to $484.99.</li>
<li>The iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) rose 1.9% to $223.63.</li>
<li>The Technology Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>) outperformed, up 0.2%. The Utilities Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>) lagged, down 0.9%.</li>
</ul>
<h1 class="wp-block-heading">Thursday&#8217;s Stock Movers</h1>
<ul>
<li>Darden Restaurants Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRI#NYSE">DRI</a>) soared 9%, in response to its quarterly earnings and bullish outlook for upcoming quarters. </li>
<li>Also reacting to earnings reports was FactSet Research Systems Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDS#NYSE">FDS</a>) up 5%.</li>
<li>Companies expected to report earnings after the close include FedEx Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>) and Lennar Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEN#NYSE">LEN</a>).</li>
</ul>
Read Next: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40937291/bank-stocks-hit-inflection-point-after-feds-50-basis-point-cut-analyst-reveal-top-p">• Bank Stocks Hit Inflection Point After Fed&#8217;s 50 Basis Point Cut, Analyst Reveals Top Picks</a> Images was created using artificial intelligence DALL-E

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Commodities

Economics

Intraday Update

ETFs

$BTC

SPDR Dow Jones Industrial Average ETF Trust

NVDA

iShares PHLX SOX Semiconductor Sector Index Fund

SOXX

Wall Street Breaks Records, Chipmakers Rally, Tesla Hits 2-Month High As Fed Cut Drives Risk-On Mode: What's Driving Markets Thursday?

On Wednesday, Hims &amp; Hers Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) launched the Service Appreciation Initiative, offering compounded GLP-1 weight loss medications to some personnel for as <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/b40918651/hims-hers-to-offer-access-to-compounded-glp-1-injections-for-as-low-as-99month-to-u-s-military-vet" rel="noreferrer noopener">low as $99 per month</a>.
The initiative covers eligible U.S. military personnel, veterans, teachers, nurses, and first responders.
Hims &amp; Hers Health is a telehealth company known for offering compounded alternatives to popular GLP-1 weight-loss treatments. Its shares have soared&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40440501/telehealth-firm-hims-hers-health-rides-high-on-demand-for-copycat-weight-loss-drugs-amid-supply-s" rel="noreferrer noopener">over 120% since August 2023</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40736321/battle-over-compounded-weight-loss-medications-sustainability-and-regulation" rel="noreferrer noopener">Battle Over Compounded Weight-Loss Medications &#8211; Sustainability and Regulation</a>
The platform has already seen success, with over 12,000 customers reporting significant weight loss—an average of 10.2 pounds with compounded GLP-1 injections and 6.3 pounds with non-GLP-1 oral medications—within four weeks of starting treatment.
The issue of obesity is particularly significant in service roles. Studies have shown that around 70% of American adults are overweight or obese, and the rates are alarmingly high among veterans, military personnel, teachers, nurses, police officers, and firefighters.
Stress, sleep disruption, and other occupational hazards contribute to these statistics, making the need for affordable weight loss solutions even more urgent.
Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>)&nbsp;CEO&nbsp;Lars Fruergaard Jørgensen has defended the high U.S. prices of the company's blockbuster drugs,&nbsp;Ozempic&nbsp;and&nbsp;Wegovy, stating that these medications are reducing the economic burden of&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40422798/doctors-struggle-to-secure-medicare-coverage-for-heart-patients-on-novo-nordisks-wegovy" rel="noreferrer noopener">obesity-related health issues</a>.
Earlier this year, a study revealed that Ozempic could be produced for less than $5 a month, starkly contrasting its current&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/03/37989566/how-much-does-it-cost-to-make-novo-nordisks-ozempic-shockingly-low-against-1-000-price-tag-study-" rel="noreferrer noopener">monthly price of $968.52</a>. Similarly, Wegovy is priced at <a target="_blank" href="https://www.benzinga.com/general/biotech/24/05/39042551/novo-nordisk-faces-scrutiny-over-high-prices-of-ozempic-and-wegovy-blames-us-health-system?utm_campaign=partner_feed&amp;utm_source=yahooFinance&amp;utm_medium=partner_feed&amp;utm_content=site&amp;nid=39600377" rel="noreferrer noopener">$1,349.02 per month</a>.
Senator Bernie Sanders, chair of the Health, Education, Labor and Pensions (HELP) Committee, has been vocal about the stark price differences for Ozempic and Wegovy between the U.S.&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/07/39736330/bernie-sanders-targets-high-prices-of-ozempic-and-wegovy-in-us" rel="noreferrer noopener">and other countries</a>.
Novo Nordisk CEO Lars Jorgensen is scheduled to appear before the Senate HELP Committee, led by Chairman Bernie Sanders, for a hearing next week that will focus on hearing popular drugs, Ozempic, <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40550961/novo-nordisk-does-not-operate-as-drug-cartel-ceo-defends-us-pricing-of-ozempic-against-criticism-" rel="noreferrer noopener">and Wegovy in the U.S.</a>
Price Action: HIMS stock is up 3.49% at $16.88 at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40927136/amazon-boosts-worker-pay-to-over-29hour-invests-2-2b-as-holiday-kicks-in" target="_blank" rel="noreferrer noopener">Amazon Boosts Worker Pay to Over $29/Hour, Invests $2.2B As Holiday Kicks In</a>.</li>
</ul>
Photo via Shutterstock

Health Care

General

Hims & Hers Health, Inc. Class A Common Stock

HIMS

Hims & Hers To Offer Access To Compounded Diabetes And Weight Loss Drugs For Just $99/Month To Certain Professional Personnel

FANG

Shares of oil and gas companies are trading higher amid a rise in the price of oil after the Fed cut rates, which could lift the demand outlook. Also, ongoing tension in the Middle East could increase supply

<a href="https://www.wsj.com/business/disney-to-stop-using-slack-following-hack-that-exposed-company-data-c5311caf?mod=latest_headlines" title="https://www.wsj.com/business/disney-to-stop-using-slack-following-hack-that-exposed-company-data-c5311caf?mod=latest_headlines">https://www.wsj.com/business/disney-to-stop-using-slack-following-hack-that-exposed-company-data-c5311caf?mod=latest_headlines</a>

Disney to Stop Using Slack Following Hack That Exposed Company Data, Many Disney Teams Had Already Started to Transition to 'Streamlined Enterprise-Wide Collaboration Tools'

Investors are always looking for stocks that are poised to beat at earnings season and KB Home&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/kbh#NYSE">KBH</a>)&nbsp;may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.
That is because KB Home is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings &mdash; with the most up-to-date information possible &mdash; is a pretty good indicator of some favorable trends underneath the surface for KBH in this report.
In fact, the Most Accurate Estimate for KBH for the to-be-reported quarter is currently pegged higher than the broader Zacks Consensus Estimate of $2.04 per share. This suggests that analysts have very recently bumped up their estimates for KBH, giving the stock a Zacks Earnings ESP of +0.08% heading into earnings season.
<h2>KB Home Price and EPS Surprise</h2>
<div class="chart_embed">
<img alt="KB Home Price and EPS Surprise" src="https://staticx-tuner.zacks.com/images/charts/2a/1726743013.png" style="height:266px; width:538px" title="" />
KB Home price-eps-surprise | KB Home Quote
</div>
<h2>Why is this Important?</h2>
A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises, and outperforming the market. Our recent 10-year backtest shows that stocks that have a positive Earnings ESP and a Zacks Rank #3 (Hold) or better show a positive surprise nearly 70% of the time, and have returned over 28% on average in annual returns.
Given that KBH has a Zacks Rank #3 and an ESP in positive territory, investors might want to consider this stock ahead of earnings.
Clearly, recent earnings estimate revisions suggest that good things are ahead for KB Home, and that a beat might be in the cards for the upcoming report.
<a href="https://www.zacks.com/stock/news/2338358/why-kb-home-kbh-might-surprise-this-earnings-season?cid=CS-BENZ-FT-tale_of_the_tape|earnings_surprise-2338358">To read this article on Zacks.com click here.</a>

Earnings Beats

Mid Cap

Why KB Home Might Surprise This Earnings Season

Macro Notification

iShares MSCI Israel Capped Investable Market Index Fund

ISRA

U.S. Defense Secretary Austin Postpones Israel Trip

A Federal Reserve focused on supporting the economy through rate cuts is a robust bullish catalyst for U.S. small-cap stocks, according to Sean Gallagher, global head of Lazard&#8217;s <a href="https://www.benzinga.com/news/small-cap">small-cap equity platform.</a>
In an exclusive interview with Benzinga, Gallagher reaffirmed his strong optimism that small caps will close the performance gap with large caps that has widened in recent years.
&#8220;The Fed is in &#8216;pro-growth mode,&#8217; and easing financial conditions are very helpful for many parts of the economy,&#8221; he stated. 
&#8220;I think laggard areas like small caps are a lot more attractive.&#8221; While Gallagher noted that the broader market isn&#8217;t cheap—given that the S&amp;P 500 trades at over 20 times its earnings—small caps remain comparatively undervalued, trading at half the S&amp;P 500&#8217;s price-to-earnings ratio.
Following the Fed&#8217;s bold decision to slash rates by 50 basis points to 4.75-5%, the Russell 2000, as tracked by the iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>), had a volatile reaction on Wednesday, closing flat for the day. 
Yet, as investors digest the decision, small caps rose by 1.7% on Thursday, outperforming larger-cap counterparts. 
Don't miss out on this unparalleled opportunity:
<ul>
<li><a href="https://www.benzinga.com/events/small-cap/global-small-cap-conference-2024/" target="_blank" rel="noreferrer noopener">Register now to secure your spot at Benzinga's Largest SmallCap Conference ever in Chicago!</a></li>
</ul>
Gallagher reiterated his call of &#8220;at least 30% upside on a 12 month basis,&#8221; <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40794070/exclusive-lazard-small-cap-expert-predicts-30-50-russell-2000-rally-on-the-back-of-%20ChatGPT%20ha%20detto:%20ChatGPT">for the Russell 2000. </a>
&#8220;There&#8217;s no question&#8221; that even the group of non-earners within the small-cap index could benefit significantly from aggressive rate cuts, such as the 50 basis point reduction, he added.
As we enter what he describes as &#8220;a pretty aggressive rate-cutting cycle,&#8221; the market could expand beyond the heavily concentrated Magnificent Seven, bringing small caps into focus for retail investors.
The expert maintains a constructive outlook on the economy, dismissing fears of a slowdown. While he acknowledges some labor market softness, he doesn&#8217;t view it as a sign of fundamental weakness.
<h3 class="wp-block-heading">Fed To Cut By 25Bps At Every Meeting</h3>
Gallagher anticipates 25 basis point rate cuts at each upcoming Fed meeting. &#8220;We&#8217;re in a much better place with inflation and are gradually getting back to trend,&#8221; he said.
He foresees a steady series of 25 basis point cuts following the initial front-loaded 50 basis point cut.
&#8220;I think we&#8217;re in a &#8216;good is good and bad is bad&#8217; kind of mindset going forward,&#8221; Gallagher said. Positive economic data will benefit the markets, whereas negative data, particularly on the labor market front, may disappoint investors. 
<h3 class="wp-block-heading">Small Caps Poised To Play Catch-Up, Biotech In Focus</h3>
Gallagher believes cyclical sectors are set to rise here. 
He is particularly optimistic about companies with lean inventories, solid balance sheets, and free cash flow, especially those enduring the current tough cycle. &#8220;When demand comes back, you&#8217;ll see meaningful appreciation,&#8221; he said.
Gallagher also sees potential in the biotech sector, noting that higher rates have been restrainting funding for years.
&#8220;We're definitely active in healthcare, looking for opportunities with companies that have diversified pipelines, solid balance sheets, and are poised to benefit when biotech funding picks up,&#8221; he added.
Don&#8217;t miss the opportunity to dominate in a volatile market at the&nbsp;<a href="https://www.benzinga.com/events/small-cap/global-small-cap-conference-2024/" target="_blank" rel="noreferrer noopener">Benzinga SmallCAP Conference on Oct. 9-10, 2024</a>,&nbsp;at the Chicago Marriott Downtown Magnificent Mile.
Get exclusive access to CEO presentations, 1:1 meetings with investors, and valuable insights from top financial experts. Whether you&#8217;re a trader, entrepreneur, or investor, this event offers unparalleled opportunities to grow your portfolio and network with industry leaders.
<a href="https://www.benzinga.com/events/small-cap/global-small-cap-conference-2024/" target="_blank" rel="noreferrer noopener">Secure your spot and get your tickets today!</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40938732/wall-street-ramps-up-interest-rate-cut-bets-after-fed-meeting-the-hard-landing-crow">Wall Street Ramps Up Interest Rate Cut Bets After Fed Meeting: &#8216;The Hard-Landing Crowd Should Disperse,&#8217; Economist Says</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Biotech

Equities

Macro Economic Events

Broad U.S. Equity ETFs

Econ #s

Federal Reserve

EXCLUSIVE: Fed In 'Pro-Growth Mode' Will Drive Small Cap Performance, Lazard Expert Says

<a href="https://www.verizon.com/about/news/back-market-and-visible-verizon-announce-us-partnership">https://www.verizon.com/about/news/back-market-and-visible-verizon-announce-us-partnership</a>
Back Market and Visible by Verizon Announce U.S. Partnership
&nbsp;
Refurbished Tech Marketplace to Feature Exclusive Visible Plan Offer&nbsp;in Time for Holiday Shopping Season
Today, <a href="https://www.backmarket.com/en-us">Back Market</a>, the leading global marketplace for Verified Refurbished tech, announced a new partnership with <a href="https://www.visible.com/">Visible</a>, Verizon's award-winning app-based wireless service, offering unlimited data, talk and messaging. The exclusive offer was unveiled by Back Market Founder and CEO, Thibaud Hug De Larauze and Visible Managing Director, Jeremy Bolton during a Paris press conference.
Available now, every smartphone purchased on Back Market will come with access to a $20/month offer on the Visible plan for the first twelve months, with standard rates applying afterwards. This is a savings of $60 per line on the Visible plan for the first year, and if you factor in the cost of a new device compared to the cost of a Verified Refurbished device on Back Market, the savings are even greater. The combined value of these two brands makes access to high-quality technology and an exceptional wireless experience more affordable than ever.
"Together, Back Market and Visible are reaching the next generation of consumers who care about sustainability and getting the best deal," said Thibaud Hug De Larauze, Founder and CEO, Back Market. "We launched this partnership to continue to provide U.S. customers more convenience, affordability, and access to refurbished tech that offers the same factory-quality devices as new, at far less cost and impact on the environment. Visible shares our commitment to growing the circular economy for consumer technology and understands that to build a sustainable business you need to start with an amazing customer experience."
"We are excited to partner with Back Market to give U.S. customers a new option that's not only affordable, but environmentally-friendly," said Jeremy Bolton, General Manager, Visible. "We've always been committed to bringing our customers the best, most innovative, and most accessible digital wireless service, and now, we're proud to do that in a way that limits the impact of technology on the environment."
In partnership with Visible, Back Market's customers are within a click of best-in-class wireless service, including unlimited data on Verizon's 5G and 4G LTE networks. With this exclusive offer, Back Market continues to be a one-stop-shop for all consumer electronic needs, especially during the upcoming holiday shopping season as shoppers look for quality, affordable devices and trusted mobile plans, all while promoting sustainability through its circular model.
Details of the exclusive Visible plan offer on Back Market include:
<ul>
<li>$20/month for 12 months followed by standard rates for the Visible plan</li>
<li>Unlimited data, talk &amp; text on Verizon's 5G &amp; 4G LTE networks</li>
<li>Coverage of 99% of the U.S. population</li>
<li>High-risk spam and robocall blocking</li>
<li>Free talk and text to Mexico &amp; Canada</li>
<li>Access to Visible's 15-day network free trial</li>
</ul>
These savings come with no trade off in quality. Customers on Back Market always receive a 30-day money-back guarantee and a one-year warranty when purchasing devices, and this year <a href="https://www.jdpower.com/business/press-releases/2024-us-wireless-retail-experience-study-volume-2">J.D. Power</a> recognized Visible for delivering the best purchase experience among value mobile virtual network operators.
Back Market's mission is to lower the environmental impact of tech by extending devices lifespans. Customers can purchase high-quality refurbished electronics and devices that are better than new at a fraction of the price.

'Back Market And Visible By Verizon Announce U.S. Partnership'

Mastercard Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>) shares are<a target="_blank" href="https://www.benzinga.com/premarket" rel="noreferrer noopener"> trading lower on Thursday.</a>
According to&nbsp;<a target="_blank" href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" rel="noreferrer noopener">Benzinga Pro</a>, MA stock has gained over 19% in the past year. Investors can gain exposure to the stock via iShares U.S. Financial Services ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IYG#NYSE">IYG</a>) and&nbsp;BlackRock Long-Term U.S. Equity ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BELT#NASDAQ">BELT</a>).
Safaricom and Mastercard have forged a partnership aimed at boosting the adoption of payment acceptance and <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/b40939900/safaricom-and-mastercard-partner-to-expand-remittances-and-payment-acceptance-to-over-636-000-merc" rel="noreferrer noopener">cross-border remittance services in Kenya.</a>
&#8220;We are proud to partner with Safaricom to build an inclusive digital economy that works for everyone, everywhere. We will enable the merchants to grow and contribute to the Kenyan economy,&#8221;&nbsp;said Amnah Ajmal, Executive Vice President, EEMEA, Mastercard.
Also Read:<a target="_blank" href="https://www.benzinga.com/markets/equities/24/07/39621550/mastercard-and-ant-group-expand-digital-payment-zones-in-western-chinese-cities-details" rel="noreferrer noopener"> Mastercard and Ant Group Expand Digital Payment Zones In Western Chinese Cities: Details</a>
This collaboration is expected to benefit more than 636,000 merchants utilizing M-PESA, Safaricom&#8217;s premier mobile money service.
By utilizing M-PESA&#8217;s vast merchant network alongside Mastercard&#8217;s global payment infrastructure, this partnership aims to provide merchants with seamless, secure, and scalable payment solutions, allowing them to reach customers in international markets.
Additionally, it will enhance remittance services, facilitating efficient cross-border transactions.
&#8220;By combining our expertise with Mastercard&#8217;s global acceptance network, we are enabling businesses to provide more efficient and frictionless payment solutions to their customers, both in Kenya and beyond,&#8221; said&nbsp;Esther Waititu, Chief Financial Services Officer, Safaricom.
Price Action: MA shares were down 0.13% at $494.11 at the last check Thursday.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/06/39502281/judge-tosses-the-card-visa-mastercard-swipe-fee-settlement-reportedly-rejected" target="_blank" rel="noreferrer noopener">Judge Tosses The Card: Visa-Mastercard Swipe Fee Settlement Reportedly Rejected</a></li>
</ul>

BELT

iShares Trust Dow Jones US Financial Services Index Fund

Safaricom, Mastercard Team Up To Supercharge Cross-Border Payments And Merchant Growth In Kenya

U.S. stocks traded higher midway through trading, with the Dow Jones index jumping more than 500 points on Thursday.
The Dow traded up 1.25% to 42,023.61 while the NASDAQ rose 2.30% to 17,976.99. The S&amp;P 500 also rose, gaining, 1.60% to 5,707.97.
Check This Out: <a href="https://www.benzinga.com/news/24/09/40937584/alphabet-mcdonalds-and-2-other-stocks-executives-are-selling">Alphabet, McDonald&#8217;s And 2 Other Stocks Executives Are Selling</a>
Leading and Lagging Sectors Information technology shares jumped by 2.9% on Thursday.
In trading on Thursday, utilities shares fell by 0.6%.
Top Headline
FactSet Research Systems Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDS#NYSE">FDS</a>) reported better-than-expected results for its fiscal fourth quarter.
The company posted quarterly sales growth of 4.9% year-on-year to $562.2 million, beating the analyst consensus estimate of $546.81 million. Adjusted EPS of $3.74 beat the analyst consensus estimate of $3.62.
FactSet said it sees fiscal 2025 revenue of $2.285 billion–$2.305 billion versus $2.301 billion estimate and adjusted EPS of $16.80–$17.40 versus consensus of $17.36.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Edgewise Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWTX#NASDAQ">EWTX</a>) shares shot up 37% to $26.23 after the company announced top-line data of EDG-7500 from the Phase 1 trial in healthy subjects and the single-dose arm of the Phase 2 CIRRUS-HCMtrial in patients with obstructive HCM.</li>
<li>Shares of Signing Day Sports, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SGN#NYSE">SGN</a>) got a boost, surging 257% to $0.4545 after the company announced it will acquire sports gaming technology company Swifty Global.</li>
<li>Mobileye Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBLY#NASDAQ">MBLY</a>) shares were also up, gaining 16% to $13.51 after Intel reportedly said it does not have plans to divest a majority interest in the company.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Haoxi Health Technology Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HAO#NASDAQ">HAO</a>) shares dropped 79% to $0.64. Haoxi Health Technology announced the pricing of a $12 million underwritten follow-on public offering of 4 million units at a price of $3 per unit.</li>
<li>Shares of Progyny, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGNY#NASDAQ">PGNY</a>) were down 30% to $17.21 after a client elected to exercise an option to terminate its services agreement with the company.</li>
<li>Vivos Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VVOS#NASDAQ">VVOS</a>) was down, falling 25% to $3.10 after the company announced a $4.3 million registered offering of 1.36 million shares of common stock at $3.15 per share.</li>
</ul>
Commodities In commodity news, oil traded up 1% to $71.64 while gold traded up 0.1% at $2,600.00.
Silver traded up 1.4% to $31.115 on Thursday, while copper rose 1.1% to $4.3445.
Euro zone
European shares were higher today. The eurozone's STOXX 600 climbed 1.35%, Germany's DAX climbed 1.66% and France's CAC 40 jumped 2.11%. Spain's IBEX 35 Index rose 0.50%, while London's FTSE 100 rose 0.85%.
The Bank of England maintained the Bank Rate at 5% during its September meeting, after cutting rates by 25 bps in August. The current account surplus in the Eurozone increased to €48 billion in July from €25.5 billion in the year-ago period.
Asia Pacific Markets
Asian markets closed higher on Thursday, with Japan's Nikkei 225 gaining 2.13%, Hong Kong's Hang Seng Index surging 2%, China's Shanghai Composite Index gaining 0.69% and India's BSE Sensex gaining 0.29%.
Hong Kong's unemployment rate came in unchanged at 3% in the three months ending August. The Hong Kong Monetary Authority cut its base rate by 50bps to 5.25% at its recent meeting.
Economics
<ul>
<li>The U.S. reported a current account deficit of $266.8 billion in the second quarter versus a gap of $241 billion in the prior period and higher than market estimates of a $260 billion gap.</li>
<li>U.S. initial jobless claims fell by 12,000 from the prior week to 219,000 in the week ending September 14, compared to market expectations of 230,000.</li>
<li>The Philadelphia Fed Manufacturing Index climbed to 1.7 in September from -7 in the previous month and topping market estimates of -1.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40937617/top-3-defensive-stocks-you-may-want-to-dump-in-september">Top 3 Defensive Stocks You May Want To Dump In September</a></li>
</ul>

Eurozone

EWTX

MBLY

PGNY

VVOS

Dow Jumps Over 500 Points; FactSet Research Posts Upbeat Earnings

On Tuesday, Theratechnologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THTX#NASDAQ">THTX</a>) warned of a potential temporary supply disruption of Egrifta SV (tesamorelin for injection) <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/g40909830/theratechnologies-announces-a-risk-of-a-temporary-supply-disruption-for-egrifta-sv-in-early-2025" rel="noreferrer noopener">in early 2025</a>.
The FDA has approved Egrifta SV as the only treatment for&nbsp;HIV-related&nbsp;excess visceral abdominal fat.
The interruption is linked to an unexpected voluntary shutdown of the contract manufacturer&#8217;s facility following an FDA inspection.
The FDA review timeline could delay the resumption of product distribution, but the company is actively working with its manufacturer and the FDA to minimize patient impact.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/07/39709482/hiv-medicine-maker-theratechnologies-wraps-up-strong-second-quarter-stock-soars" rel="noreferrer noopener">HIV Medicine Maker Theratechnologies&#8217; Wraps Up Strong Second Quarter,&#8217; Stock Soars</a>
Paul Lévesque, President and CEO of Theratechnologies, expressed confidence that patient needs in 2025 will be met despite this disruption.
To mitigate the risk of shortages, Theratechnologies plans to implement measures to manage Egrifta SV inventory levels through early January 2025.
However, due to the supply challenges, the company anticipates a revenue shortfall of approximately $1.6 million for its fiscal year 2024.
The contract manufacturer&#8217;s facility underwent a voluntary three-month shutdown to address observations made by the FDA&#8217;s Office of Compliance, which were unrelated to the Egrifta SV manufacturing process but concerned the facility&#8217;s environment.
The manufacturer aims to resume operations by mid-October, with the first batch of Egrifta SV slated for production on October 21.
Theratechnologies must file a Prior Approval Supplement (PAS) with the FDA detailing changes made at the facility, which is expected around the manufacturing date. The FDA typically reviews PAS filings within four months.
As the company&#8217;s annual <a target="_blank" href="https://www.theratech.com/static-files/e2cd4c2e-6d00-4f3d-9197-f588856fa98e" rel="noreferrer noopener">filing</a>, it does not own or operate its manufacturing facilities and relies on third-party suppliers, such as Bachem, Jubilant, and Lyophilization Services of New England, to produce Egrifta SV.
The company has not qualified alternative manufacturers, and the validation process for new suppliers could take up to three years, complicating any potential transition.
Price Action: THTX Stock is up 4.16% at $1.25 at the last check on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/09/40938804/gamestop-ceo-ryan-cohen-penalized-nearly-1m-over-wells-fargo-share-acquisition" target="_blank" rel="noreferrer noopener">GameStop CEO Ryan Cohen Penalized Nearly $1M Over Wells Fargo Share Acquisition</a>.</li>
</ul>

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

GBX Intl Gr

GBX Intl Gr (GBXI) Forecast

GBX Intl Gr (OTC:GBXI) Stock, Quote.Headers.trade-ideas